I think that this bill, looking through the select committee process, the 36 submissions, I thought all of them added value and I thought there were particularly interesting parts segueing into what the therapeutic products bill may eventually become with discussions around natural products, alternative products, and this indeed sitting as a cosmetic. I think part of that discovery has exposed other parts of the process. If we look at where this bill is working, it's working at performance standards and product claims. It was interesting to note that the manufacturing component currently has no statutory legislation, and so that may well be covered in the therapeutic products bill, be that good manufacturing practice or whatever manufacturing standard is determined. It's another part of this process that makes it even better.